PatientsVille.com Logo


Schiff Medical Research Studies

Up-to-date List of Schiff Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Schiff Medical Research Studies

Rank Status Study
1 Unknown  Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis
Condition: Osteoarthritis
Intervention: Drug: Chondroitin sulfate + Glucosamine sulfate
Outcome Measures: Promotion of pain relief in patients with osteoarthritis.;   Functional capacity, overall assessment of clinical improvement, assessment of adverse events
2 Recruiting Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis
Condition: Knee Osteoarthritis
Interventions: Drug: Chondroitin sulfate + glucosamine sulfate;   Drug: Placebo
Outcome Measures: Reduction of pain using VAS;   OMERACT-OARSI responder criteria;   WOMAC Index (pain, stiffness and function);   Investigator global assessment;   Patient global assessment;   Consumption of rescue medication;   Adverse events recording
3 Unknown  Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
Condition: Chronic Hepatitis C
Intervention: Drug: omega-3 fatty acid
Outcome Measures: The effect of omega three fatty acids would be estimated through two questionnaires which filled by the patients monthly;   with the BDI questionnaire which estimates the level of depression of the patient and;   the SF36 questionnaire which provides information about the overall influence of a disease upon a patient's daily life and mental status.;   Secondary outcome measures include monthly results of biochemical and hematologic blood tests, including levels of:;   albumin;   bilirubin;   ALT;   CRP;   hemoglobin;   WBC;   platelets
4 Unknown  Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients
Condition: Xerostomia
Intervention: Behavioral: hypnosis
Outcome Measures: salivaa volume;   quality of life related to salivation
5 Recruiting The Effect of Complementary Medicine (CAM) Treatments on Common Symptoms in Hospitalized Patients
Conditions: Pain;   Nausea;   Anxiety
Intervention: Other: CAM treatments
Outcome Measures: Symptomatic relief expressed in Visual Analogue Scales from asymptomatic 0-100 extremely symptomatic;   correlations between expectations from CAM as measured on a likert scale (0= disbelief and 5- high belief)and primary outcomes
6 Unknown  MEDIR Medulloblastome
Condition: Child Cancer Brain
Intervention: Other: IRMf Bold
Outcome Measure:
7 Unknown  Non-inferiority Study of the Glucosamine Sulfate + Chondroitin Sulfate Association Capsule in Comparison to the CONDROFLEX® Product in Osteoarthrosis of the Knee
Condition: Osteoarthritis, Knee
Interventions: Drug: Glucosamine sulfate + chondroitin sulfate - MANTECORP;   Drug: Glucosamine sulfate + chondroitin sulfate - CONDROFLEX
Outcome Measures: WOMAC Index;   Paracetamol use;   Adverse events;   Subjective assessment of response to therapy by the investigator and patient;   Subjective evaluation of tolerability graded as excellent, good, regular or poor
8 Recruiting Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Conditions: Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions: Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Outcome Measures: Progression-free survival (PFS);   Overall survival (OS);   Quality of life as assessed by the FACT-BR questionnaire at baseline, annually until disease progression, and at the time of disease progression;   Neurocognitive functioning as assessed at baseline, annually until disease progression, and at the time of disease progression;   Correlation of pre-treatment 1p and 19q levels in tumor tissue samples with PFS and OS
9 Recruiting Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Biological: anti-endoglin monoclonal antibody TRC105;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
Outcome Measures: MTD of TRC105 combined with bevacizumab based on the incidence of dose-limiting toxicity (DLT) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 (Phase I);   Progression-free survival (PFS) (Phase II);   Overall survival (Phase I and II);   PFS (Phase II);   Incidence of adverse events as assessed by NCI CTCAE v. 4.0 (Phase II);   QOL as assessed by the EORTC QLQ-C15-PAL and QLQ-BN20 Patient Questionnaires and the WIWI questionnaire (Phase II);   Objective response (Phase I);   Time until any treatment-related toxicity (Phase I);   Time until treatment-related grade 3+ toxicity (Phase I);   Time to progression (Phase I);   Time to treatment failure (Phase I)
10 Recruiting Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
Condition: Normal and Diseased Tissue and Body Fluids Samples
Outcome Measure: Collecting, processing and archiving human tissue
11 Recruiting Mature B-Cell Lymphoma And Leukemia Study III
Condition: Mature B-Cell Lymphoma
Interventions: Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
Outcome Measures: To perform transcriptional profiling and genome-wide analysis of DNA copy number abnormalities and loss-of-heterozygosity using DNA microarrays in children with newly diagnosed mature B cell lymphomas;   To describe the types and frequency of mutations in the ARF-HDM2-TP53 pathway, in B-cell lymphomas in the United States and those found in selected geographic regions of the world.;   To describe the expression of ARF-HDM2-TP53 and PUMA-associated pathways in B-cell lymphomas in the United States and that found in B-cell lymphomas of other selected geographic regions of the world;   To describe the pattern and frequency of XLP gene mutations presenting with B-cell lymphomas in the United States and selected geographic regions.;   To describe the pattern of EBV protein expression (e.g., EBNA 3) in EBV-positive lymphomas and to compare patterns of EBV protein expression with clinical, laboratory and outcome data.;   Complete response rate, event-free survival and overall survival
12 Recruiting Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Drug: Clofarabine
Outcome Measures: To compare the immunologic complete response rate after one course of therapy in patients who receive cytarabine + daunorubicin + etoposide (ADE) with that in patients who receive clofarabine + cytarabine (Clo/AraC);   Event-free survival of standard risk patients who receive chemotherapy alone.;   Event-free survival of standard risk patients who receive chemotherapy followed by natural killer cell transplantation.
13 Recruiting Molecular Classification of Head and Neck Tumors Using cDNA Microarray Analysis to Detect Prognosis and Response to Therapy
Condition: Head and Neck Neoplasms
Outcome Measures: correlation of treatment response and prognosis (time to recurrence and survival) with genetic expression profile;   identify a series of diagnostic markers for head and neck tumors and study the mechanism of action of these proteins
14 Recruiting Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device;   Drug: Temozolomide
Outcome Measures: Progression Free Survival (PFS) time;   Overall survival (OS)
15 Recruiting ANG1005 in Patients With Recurrent High-Grade Glioma
Conditions: Glioma;   Glioblastoma;   Brain Tumor, Recurrent
Interventions: Drug: ANG1005;   Drug: Bevacizumab
Outcome Measures: Objective Response Rate (ORR) (Arms 1 and 3);   PFS3 (Arm 2);   ORR in Arm 2;   PFS at 3, 6 and 12 months;   Median PFS;   Duration of response;   Overall survival;   Safety and tolerability;   Pharmacokinetics
16 Recruiting HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Condition: Hepatitis C
Outcome Measures: Sustained virological response (SVR);   Treatment persistence;   Virological breakthrough;   Management of adverse events
17 Recruiting Liver Fibrosis in Sickle Cell Disease
Condition: Sickle Cell Disease
Interventions: Other: Liver transient elastography;   Other: magnetic resonance imaging R2*
Outcome Measures: Liver transient elastography (FibroScan) of liver iron content and stiffness;   magnetic resonance imaging (MRI) measure of liver iron content and stiffness;   liver function tests (ALT, AST, serum alkaline phosphate, GGTP, total bilirubin, direct bilirubin), complete blood count, platelets, reticulocyte count, serum ferritin to assess liver function and evaluate overall health
18 Recruiting Amgen 386 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: Amgen 386;   Drug: Bevacizumab
Outcome Measures: Radiological response rates;   Radiographic response and Median progression free survival and overall survival.
19 Recruiting A Pilot Study of the Use of the DaVinci Robotic System for Otorhinolaryngology-Head and Neck Surgery
Condition: Head and Neck Neoplasms
Intervention: Device: robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System
Outcome Measures: ability to adequately visualize the operative field and complete planned surgery;   complication rate compared to standard endoscopic and minimally invasive procedures;   blood loss compared to historical controls of endoscopic and minimally invasive procedures;   quality of life at early (1-3 months) and late (one year);   number of days hospitalized immediately after surgery;   Time to recurrence of tumor or other pathology for which procedure was performed;   Time from start of treatment to death
20 Recruiting Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: bevacizumab;   Drug: pemetrexed disodium
Outcome Measures: Overall survival;   Progression-free survival;   Objective response as measured by RECIST;   Toxicity;   Association between bevacizumab and pemetrexed disodium population pharmacokinetics;   Association between proteomic profiles and ICAM, VEGF, and FGF-beta with the clinical outcomes (Closed as of 04/01/2010)

These studies may lead to new treatments and are adding insight into Schiff etiology and treatment.

A major focus of Schiff research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Schiff